NASDAQ : MNOV

MediciNova, Inc. — Company profile

Healthcare · Biotechnology · United States

Last price 1.4 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 68.91M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Company profile

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2 clinical trial for treating neurological and other disorders, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, and glioblastoma, as well as prevention of acute respiratory distress syndrome. The company is also developing MN-001 (tipelukast), an orally bioavailable small molecule compound in Phase 2 clinical trial to treat fibrotic and other metabolic disorders, including nonalcoholic fatty liver disease and hypertriglycedemia. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California.

Details

NameMediciNova, Inc.
SectorHealthcare
IndustryBiotechnology
Employees6
Founded2000
Ipo Date2005-02-08
CeoYuichi Iwaki
CountryUnited States
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
IsinUS58468P2065
Cusip58468P206
Cik0001226616
Sic2834
Stock TypeCommon Stock

Key executives

NameTitle
Dr. Yuichi Iwaki M.D., Ph.D.Co-Founder, President, Chief Executive Officer and Chairman
Dr. Kazuko Matsuda M.D., M.P.H., Ph.D.Senior Vice President, Chief Medical Officer and Director
Dr. David H. Crean M.B.A., Ph.D.Chief Business Officer
Jason J. Kruger CPAChief Financial Officer and Principal Financial Officer

Contact

Address4275 Executive Square, Suite 300, La Jolla, California 92037, United States
Phone858 373 1500
Websitehttps://medicinova.com